Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

126.92USD
26 May 2017
Change (% chg)

$-0.61 (-0.48%)
Prev Close
$127.53
Open
$127.23
Day's High
$127.67
Day's Low
$126.83
Volume
1,093,155
Avg. Vol
2,027,737
52-wk High
$129.00
52-wk Low
$109.32

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $341,901.31
Shares Outstanding(Mil.): 2,693.83
Dividend: 0.84
Yield (%): 2.65

Financials

  JNJ.N Industry Sector
P/E (TTM): 21.34 14.27 17.41
EPS (TTM): 5.95 -- --
ROI: 14.11 -7.17 -5.42
ROE: 23.09 -6.63 -4.68

J&J's Ethicon hit with $2.16 million verdict in vaginal-mesh case

A state court jury in Philadelphia on Friday ordered Johnson & Johnson to pay $2.16 million to a Pennsylvania woman who claimed she suffered injuries due to pelvic mesh devices manufactured by the company's Ethicon unit.

May 26 2017

Bayer, J&J to face second trial over Xarelto bleeding risks

Bayer AG and Johnson & Johnson are set to return to a New Orleans federal courthouse on Tuesday with a goal of scoring their second trial win amid thousands of lawsuits blaming injuries on the blood thinner Xarelto.

May 25 2017

MDL Watch: Consolidation sought in Physiomesh, FieldTurf and MonaVie juice cases

By Barbara Grzincic A federal judicial panel is set to weigh requests to create multidistrict litigation for Physiomesh product-liability claims against Johnson & Johnson and Ethicon, and for the marketing and sales practices claims involving MonaVie juice and concentrates, FieldTurf artificial playing surfaces and Prevagen “memory-boosting” supplements.

May 24 2017

J&J settles drug manufacturing probe by U.S. states for $33 mln

Johnson & Johnson has agreed to pay $33 million to resolve charges by most U.S. states that it misrepresented the manufacturing practices behind Tylenol, Motrin, Benadryl and other over-the-counter drugs that were eventually recalled.

May 24 2017

J&J settles drug manufacturing probe by U.S. states for $33 million

Johnson & Johnson has agreed to pay $33 million to resolve charges by most U.S. states that it misrepresented the manufacturing practices behind several over-the-counter drugs that were eventually recalled.

May 24 2017

J&J settles drug manufacturing probe by U.S. states for $33 million

Johnson & Johnson has agreed to pay $33 million to resolve charges by most U.S. states that it misrepresented the manufacturing practices behind Tylenol, Motrin, Benadryl and other over-the-counter drugs that were eventually recalled.

May 24 2017

UPDATE 1-J&J settles drug manufacturing probe by U.S. states for $33 mln

May 24 Johnson & Johnson has agreed to pay $33 million to resolve charges by most U.S. states that it misrepresented the manufacturing practices behind Tylenol, Motrin, Benadryl and other over-the-counter drugs that were eventually recalled.

May 24 2017

J&J settles drug manufacturing probe by U.S. states for $33 million

May 24 Johnson & Johnson has agreed to pay $33 million to resolve charges by most U.S. states that it misrepresented the manufacturing practices behind several over-the-counter drugs that were eventually recalled.

May 24 2017

Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy

SEOUL A unit of healthcare conglomerate Johnson & Johnson filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea's Samsung Bioepis Co Ltd from being sold in the United States.

May 19 2017

Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy

SEOUL A unit of healthcare conglomerate Johnson & Johnson filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea's Samsung Bioepis Co Ltd from being sold in the United States.

May 18 2017

More From Around the Web

Earnings vs. Estimates